About Genpharmasec Limited
Data last updated: 13 July 2026
Genpharmasec Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 16 November 1992, the company has been in operation for over 34 years.
Registered with ROC Mumbai under CIN L24231MH1992PLC323914. Listed on BSE: 531592.
Capital: an authorised share capital of ₹56 Cr and a paid-up capital of ₹55.37 Cr. Formerly known as Generic Pharmasec Limited and Adi Rasayan Limited. It is led by directors including Rajesh Mirchumal Sadhwani and Sneha Sadhwani.
Last AGM: 29 September 2025. Financial statements filed for year ended 31 March 2025. Office: Mumbai, Maharashtra.
As per BSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹139.94 Cr, reflecting significant growth compared to the previous year. The net worth stands at ₹65.64 Cr (up 0.56% YoY). Total assets are valued at ₹138.15 Cr (up 72.92% YoY).
The company is associated with 1 brand - Genpharmasec. As per MCA filings, the company has open charges of ₹12.5 Cr and satisfied charges of ₹30.35 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website genpharmasec.com.
-
EmailLocked
-
TelephoneLocked
-
Website
-
Social MediaLocked
-
Registered AddressOffice No. 104 & 105 1St Floor Gundecha Industrial Premises Co – Op Soc. Ltd.Akurli Road Kand, Ivali East, Mumbai, Maharashtra, India – 400101
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Genpharmasec Limited
Genpharmasec Limited has undergone 3 name changes throughout its history. The company was previously known as Generic Pharmasec Limited, Adi Rasayan Limited, and Sun Face Pharmasec Limited. The current legal name is Genpharmasec Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Genpharmasec Limited | Current |
| Generic Pharmasec Limited | Previous |
| Adi Rasayan Limited | Previous |
| Sun Face Pharmasec Limited | Previous |
CIN History of Genpharmasec Limited
Genpharmasec Limited has one previous CIN (Corporate Identification Number): L24231GJ1992PLC018572. The current CIN is L24231MH1992PLC323914, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24231MH1992PLC323914 | Current |
| L24231GJ1992PLC018572 | Previous |
Associated Brands with Genpharmasec Limited
Genpharmasec Limited operates one associated brand: Genpharmasec. These brands represent Genpharmasec Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical products and services are provided and distributed. | genpharmasec.com |
Business Activity of Genpharmasec Limited
Genpharmasec Limited is engaged in the principal business activity of trade, with detailed activities including wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | Locked |
Business activity turnover details for Genpharmasec Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Genpharmasec Limited
Genpharmasec Limited is audited by Bilimoria Mehta & Co. (ICAI peer reviewed, certificate valid till 2027-06-30) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| Bilimoria Mehta & Co. (ICAI peer reviewed, certificate valid till 2027-06-30) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Genpharmasec Limited
Genpharmasec Limited is currently managed by 6 directors, with 19 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rajesh Mirchumal Sadhwani | Director | 02 Jan 2019 | 7 Years 7 Months | Current |
|
Sneha Sadhwani
Also directs:
Genpharmasec Limited
|
Director | 02 Jan 2019 | 7 Years 7 Months | Current |
|
Sachin Prakash Aphandkar
Also directs:
Genpharmasec Limited
|
Director | 01 Nov 2022 | 3 Years 9 Months | Current |
|
Sohan Chaturvedi
Also directs:
Genpharmasec Limited, Clinigenome India Private Limited, Muzali Arts Limited and 1 more
|
Whole-Time Director | 26 Apr 2024 | 2 Years 3 Months | Current |
| Siddhesh Shankar Shende | Director | 04 Jul 2022 | 4 Years 1 Months | Current |
|
Mayur Bhatt
Also directs:
Genpharmasec Limited, R M Drip And Sprinklers Systems Limited
|
Director | 01 Nov 2022 | 3 Years 9 Months | Current |
Financials of Genpharmasec Limited FY 2026 filings available
Genpharmasec Limited reported revenue of ₹139.94 Cr (up 314.98% YoY) for FY 2026.
| Metrics | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Revenue from Operations | ₹139.94 Cr | ₹33.72 Cr | ₹30.41 Cr |
| Other Income | ₹3.16 Cr | ₹3.06 Cr | ₹65.59 Lakh |
| Total Income | ₹143.09 Cr | ₹36.78 Cr | ₹31.06 Cr |
| Cost of Materials Consumed | ₹2.84 Cr | ₹87.21 Lakh | ₹0 |
| Purchases of Stock-in-Trade | ₹131.4 Cr | ₹28.07 Cr | ₹23.4 Cr |
| Changes in Inventories | -₹5.66 Cr | ₹60.9 Lakh | ₹83.33 Lakh |
| Employee Benefit Expense | ₹3.87 Cr | ₹98.87 Lakh | ₹76.43 Lakh |
| Finance Costs | ₹1.24 Cr | ₹43.48 Lakh | ₹40.91 Lakh |
| Depreciation & Amortisation | ₹2.17 Cr | ₹81.15 Lakh | ₹4.21 Lakh |
| Other Expenses | ₹6.27 Cr | ₹3.12 Cr | ₹5.36 Cr |
| Total Expenses | ₹142.12 Cr | ₹34.9 Cr | ₹30.81 Cr |
| Profit Before Exceptional Items & Tax | ₹97.07 Lakh | ₹1.88 Cr | ₹25.06 Lakh |
| Exceptional Items | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹97.07 Lakh | ₹1.88 Cr | ₹25.06 Lakh |
| Total Tax Expense | ₹41.06 Lakh | ₹64.9 Lakh | ₹41.99 Lakh |
| Net Profit | ₹56.01 Lakh | ₹1.23 Cr | -₹16.94 Lakh |
| attributable to Owners | ₹1.6 Cr | ₹0 | -₹12.56 Lakh |
| attributable to NCI | -₹1.04 Cr | ₹0 | -₹4.38 Lakh |
| Other Comprehensive Income | -₹50.17 Lakh | -₹48.65 Lakh | -₹73.04 Lakh |
| Total Comprehensive Income | ₹5.84 Lakh | ₹74.47 Lakh | -₹89.97 Lakh |
| EBITDA (computed) | ₹4.38 Cr | ₹3.13 Cr | ₹70.18 Lakh |
| Basic EPS | ₹0.01 | ₹0.01 | ₹0.00 |
| Diluted EPS | ₹0.01 | ₹0.01 | ₹0.00 |
| Metrics | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Total Assets | ₹138.15 Cr | ₹79.89 Cr | ₹71.13 Cr |
| Non-current Assets | ₹57.63 Cr | ₹51.74 Cr | ₹30.28 Cr |
| Current Assets | ₹80.52 Cr | ₹28.16 Cr | ₹40.85 Cr |
| Property, Plant & Equipment | ₹21.31 Cr | ₹5.56 Cr | ₹83.9 Lakh |
| Inventories | ₹13.88 Cr | ₹8.2 Cr | ₹8.84 Cr |
| Trade Receivables | ₹29.27 Cr | ₹13.6 Cr | ₹9.1 Cr |
| Cash & Equivalents | ₹97.41 Lakh | ₹65.02 Lakh | ₹3.17 Cr |
| Equity (Net Worth) | ₹65.64 Cr | ₹65.28 Cr | ₹64.53 Cr |
| Equity Share Capital | ₹55.37 Cr | ₹55.37 Cr | ₹55.37 Cr |
| Borrowings (Non-current) | ₹23.97 Cr | ₹3.15 Cr | ₹3.21 Cr |
| Borrowings (Current) | ₹9 Cr | ₹0 | ₹0 |
| Total Debt (computed) | ₹32.98 Cr | ₹3.15 Cr | ₹3.21 Cr |
| Current Liabilities | ₹47.03 Cr | ₹9.84 Cr | ₹2.7 Cr |
| Total Liabilities | ₹72.51 Cr | ₹14.61 Cr | ₹6.59 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Operating Cash Flow | -₹17.55 Cr | ₹3 Cr | -₹3.68 Cr |
| Investing Cash Flow | ₹13.26 Cr | -₹15.31 Cr | -₹27.35 Cr |
| Financing Cash Flow | ₹3.92 Cr | -₹1.25 Cr | ₹47.86 Cr |
| Capital Expenditure | ₹52.09 Lakh | ₹5.71 Cr | ₹0 |
| Free Cash Flow (computed) | -₹18.07 Cr | -₹2.71 Cr | -₹3.68 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹36.74 Lakh | -₹13.56 Cr | ₹16.84 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹55.43 Cr | ₹39.83 Cr | ₹32.64 Cr | ₹12.04 Cr | ₹14.01 Cr | ₹8.48 Cr | ₹6.03 Cr | ₹5.19 Cr |
| Other Income | ₹1.02 Cr | ₹98.18 Lakh | ₹46.48 Lakh | ₹69.48 Lakh | ₹93.68 Lakh | ₹81.2 Lakh | ₹74.74 Lakh | ₹56.7 Lakh |
| Total Income | ₹56.44 Cr | ₹40.81 Cr | ₹33.1 Cr | ₹12.74 Cr | ₹14.95 Cr | ₹9.3 Cr | ₹6.78 Cr | ₹5.76 Cr |
| Cost of Materials Consumed | ₹12.32 Lakh | ₹1.7 Cr | ₹88.77 Lakh | ₹12.86 Lakh | ₹37.94 Lakh | ₹2.25 Lakh | ₹11.1 Lakh | ₹0 |
| Purchases of Stock-in-Trade | ₹46.55 Cr | ₹33.85 Cr | ₹39.78 Cr | ₹10.75 Cr | ₹9.49 Cr | ₹7.88 Cr | ₹5.36 Cr | ₹5.67 Cr |
| Changes in Inventories | ₹3.47 Cr | ₹2.2 Cr | -₹10.29 Cr | -₹1.05 Cr | ₹4.09 Cr | -₹1.47 Cr | -₹48.89 Lakh | -₹1.52 Cr |
| Employee Benefit Expense | ₹1.07 Cr | ₹1.25 Cr | ₹1.2 Cr | ₹34.96 Lakh | ₹31.03 Lakh | ₹30.93 Lakh | ₹19.32 Lakh | ₹17.58 Lakh |
| Finance Costs | ₹48.11 Lakh | ₹41.14 Lakh | ₹22.52 Lakh | ₹12.26 Lakh | ₹10.64 Lakh | ₹15.7 Lakh | ₹6.96 Lakh | ₹10.19 Lakh |
| Depreciation & Amortisation | ₹67.53 Lakh | ₹66.5 Lakh | ₹56.21 Lakh | ₹26.59 Lakh | ₹25.65 Lakh | ₹9.87 Lakh | ₹30.03 Lakh | ₹15.6 Lakh |
| Other Expenses | ₹2.22 Cr | ₹2.06 Cr | ₹1.54 Cr | ₹92 Lakh | ₹73.63 Lakh | ₹1.01 Cr | ₹72.82 Lakh | ₹68.68 Lakh |
| Total Expenses | ₹54.59 Cr | ₹42.14 Cr | ₹33.9 Cr | ₹11.49 Cr | ₹15.37 Cr | ₹8 Cr | ₹6.28 Cr | ₹5.27 Cr |
| Profit Before Exceptional Items & Tax | ₹1.85 Cr | -₹1.33 Cr | -₹79.6 Lakh | ₹1.25 Cr | -₹42.59 Lakh | ₹1.29 Cr | ₹50.47 Lakh | ₹48.7 Lakh |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹1.85 Cr | -₹1.33 Cr | -₹79.6 Lakh | ₹1.25 Cr | -₹42.59 Lakh | ₹1.29 Cr | ₹50.47 Lakh | ₹48.7 Lakh |
| Total Tax Expense | ₹49.98 Lakh | -₹50.03 Lakh | ₹38.02 Lakh | ₹3.09 Lakh | -₹15.49 Lakh | ₹51.19 Lakh | -₹19.89 Lakh | ₹20.02 Lakh |
| Net Profit | ₹1.35 Cr | -₹83.2 Lakh | -₹1.18 Cr | ₹1.22 Cr | -₹27.1 Lakh | ₹77.97 Lakh | ₹70.37 Lakh | ₹28.68 Lakh |
| attributable to Owners | ₹1.23 Cr | -₹43.12 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| attributable to NCI | ₹12.72 Lakh | -₹40.07 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Other Comprehensive Income | -₹40.65 Lakh | -₹6.22 Lakh | -₹18.07 Lakh | ₹14.26 Lakh | -₹46.69 Lakh | -₹9.19 Lakh | -₹15.18 Lakh | ₹22.42 Lakh |
| Total Comprehensive Income | ₹94.65 Lakh | -₹89.42 Lakh | -₹1.36 Cr | ₹1.36 Cr | -₹73.79 Lakh | ₹68.78 Lakh | ₹55.18 Lakh | ₹51.1 Lakh |
| EBITDA (computed) | ₹3.01 Cr | -₹25.59 Lakh | -₹87,000 | ₹1.63 Cr | -₹6.3 Lakh | ₹1.55 Cr | ₹87.46 Lakh | ₹74.5 Lakh |
| Basic EPS | ₹0.02 | ₹-0.02 | ₹-0.02 | ₹0.02 | ₹-0.01 | ₹0.01 | ₹0.01 | ₹0.01 |
| Diluted EPS | ₹0.02 | ₹-0.02 | ₹-0.02 | ₹0.02 | ₹-0.01 | ₹0.01 | ₹0.01 | ₹0.01 |
| Segment · Q4 FY26 (latest quarter) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Pharmaceuticals | ₹51.66 Cr | ₹3.11 Cr | ₹61.89 Cr | ₹38.56 Cr |
| Laboratory Testing | ₹0 | -₹43.94 Lakh | ₹7.53 Cr | ₹1.37 Cr |
| Manufacturing & Processing | ₹3.76 Cr | -₹33.14 Lakh | ₹29.92 Cr | ₹11.94 Cr |
| Unallocable | ₹0 | -₹56,000 | ₹38.81 Cr | ₹20.63 Cr |
| Segment · FY 2026 (annual) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Pharmaceuticals | ₹130.87 Cr | ₹7.03 Cr | - | - |
| Laboratory Testing | ₹1 Cr | -₹1.59 Cr | - | - |
| Manufacturing & Processing | ₹8.06 Cr | -₹3.22 Cr | - | - |
| Unallocable | ₹0 | -₹65,000 | - | - |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹131.35 Cr | ₹32.96 Cr | ₹30.41 Cr | ₹25.52 Cr | ₹27.32 Cr | ₹21.31 Cr | ₹16.5 Cr | ₹37.51 Lakh |
| Other Income | ₹4.87 Cr | ₹3.43 Cr | ₹71.76 Lakh | ₹10.01 Lakh | ₹9.26 Lakh | ₹32.78 Lakh | ₹56.28 Lakh | ₹37.5 Lakh |
| Total Income | ₹136.22 Cr | ₹36.39 Cr | ₹31.12 Cr | ₹25.62 Cr | ₹27.41 Cr | ₹21.64 Cr | ₹17.06 Cr | ₹75.01 Lakh |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹131.4 Cr | ₹28.47 Cr | ₹23.4 Cr | ₹23.18 Cr | ₹28.77 Cr | ₹23.42 Cr | ₹13.45 Cr | ₹5.25 Cr |
| Changes in Inventories | -₹5.33 Cr | ₹66.92 Lakh | ₹83.33 Lakh | ₹21.34 Lakh | -₹2.21 Cr | -₹4.22 Cr | ₹1.79 Cr | -₹5.25 Cr |
| Employee Benefit Expense | ₹97.27 Lakh | ₹66.81 Lakh | ₹76.43 Lakh | ₹53.67 Lakh | ₹25.45 Lakh | ₹18.75 Lakh | ₹12.92 Lakh | ₹1.7 Lakh |
| Finance Costs | ₹59.36 Lakh | ₹27.75 Lakh | ₹39.46 Lakh | ₹5.6 Lakh | ₹0 | ₹0 | ₹0 | ₹0 |
| Depreciation & Amortisation | ₹25.6 Lakh | ₹13.31 Lakh | ₹1.67 Lakh | ₹1.97 Lakh | ₹1.42 Lakh | ₹1.25 Lakh | ₹49,000 | ₹2,000 |
| Other Expenses | ₹1.89 Cr | ₹2.72 Cr | ₹5.25 Cr | ₹1.32 Cr | ₹1.02 Cr | ₹72.54 Lakh | ₹48.84 Lakh | ₹44.53 Lakh |
| Total Expenses | ₹129.78 Cr | ₹32.95 Cr | ₹30.66 Cr | ₹25.33 Cr | ₹27.86 Cr | ₹20.13 Cr | ₹15.86 Cr | ₹46.25 Lakh |
| Profit Before Exceptional Items & Tax | ₹6.44 Cr | ₹3.45 Cr | ₹46.66 Lakh | ₹28.15 Lakh | -₹44.3 Lakh | ₹1.51 Cr | ₹1.21 Cr | ₹28.76 Lakh |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹6.44 Cr | ₹3.45 Cr | ₹46.66 Lakh | ₹28.15 Lakh | -₹44.3 Lakh | ₹1.51 Cr | ₹1.21 Cr | ₹28.76 Lakh |
| Total Tax Expense | ₹98.73 Lakh | ₹97.77 Lakh | ₹42.04 Lakh | -₹84.32 Lakh | -₹23.37 Lakh | ₹25.1 Lakh | ₹19.6 Lakh | ₹5.64 Lakh |
| Net Profit | ₹5.45 Cr | ₹2.47 Cr | ₹4.62 Lakh | ₹1.12 Cr | -₹20.93 Lakh | ₹1.26 Cr | ₹1.01 Cr | ₹23.12 Lakh |
| Other Comprehensive Income | -₹50.29 Lakh | -₹48.65 Lakh | -₹73.04 Lakh | -₹1.16 Cr | -₹5.08 Cr | -₹4.13 Cr | -₹3.58 Cr | -₹61.58 Lakh |
| Total Comprehensive Income | ₹4.95 Cr | ₹1.98 Cr | -₹68.42 Lakh | -₹3.93 Lakh | -₹5.29 Cr | -₹2.87 Cr | -₹2.57 Cr | -₹38.46 Lakh |
| EBITDA (computed) | ₹7.29 Cr | ₹3.86 Cr | ₹87.8 Lakh | ₹35.72 Lakh | -₹42.88 Lakh | ₹1.52 Cr | ₹1.21 Cr | ₹28.78 Lakh |
| Basic EPS | ₹0.10 | ₹0.04 | ₹0.00 | ₹0.04 | ₹-0.01 | ₹0.05 | ₹0.05 | ₹0.03 |
| Diluted EPS | ₹0.10 | ₹0.04 | ₹0.00 | ₹0.04 | ₹-0.01 | ₹0.05 | ₹0.02 | ₹0.00 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹110.06 Cr | ₹79.09 Cr | ₹70.47 Cr | ₹19.88 Cr | ₹21.65 Cr | ₹27.82 Cr | ₹24.76 Cr | ₹21.7 Cr |
| Non-current Assets | ₹48.29 Cr | ₹51.26 Cr | ₹30.44 Cr | ₹94.61 Lakh | ₹10.66 Lakh | ₹1.04 Cr | ₹8.87 Cr | ₹13.95 Cr |
| Current Assets | ₹61.77 Cr | ₹27.83 Cr | ₹40.04 Cr | ₹18.93 Cr | ₹21.54 Cr | ₹26.78 Cr | ₹15.88 Cr | ₹7.75 Cr |
| Property, Plant & Equipment | ₹10.77 Lakh | ₹9.11 Lakh | ₹10.16 Lakh | ₹10 Lakh | ₹10.37 Lakh | ₹4.83 Lakh | ₹4.83 Lakh | ₹7,000 |
| Inventories | ₹12.58 Cr | ₹8.14 Cr | ₹8.84 Cr | ₹9.68 Cr | ₹9.89 Cr | ₹7.68 Cr | ₹3.46 Cr | ₹0 |
| Trade Receivables | ₹28.02 Cr | ₹13.39 Cr | ₹9.1 Cr | ₹5.71 Cr | ₹6.45 Cr | ₹7.52 Cr | ₹0 | ₹0 |
| Cash & Equivalents | ₹79.13 Lakh | ₹52.25 Lakh | ₹2.92 Cr | ₹39.76 Lakh | ₹1.61 Cr | ₹3.53 Cr | ₹2.58 Cr | ₹5.2 Cr |
| Equity (Net Worth) | ₹71.5 Cr | ₹66.55 Cr | ₹64.57 Cr | ₹15.33 Cr | ₹15.37 Cr | ₹20.66 Cr | ₹19.03 Cr | ₹21.61 Cr |
| Equity Share Capital | ₹55.37 Cr | ₹55.37 Cr | ₹55.37 Cr | ₹27.69 Cr | ₹27.69 Cr | ₹27.69 Cr | ₹21.69 Cr | ₹21.69 Cr |
| Borrowings (Non-current) | ₹3.93 Cr | ₹3.15 Cr | ₹3.21 Cr | ₹2.48 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| Borrowings (Current) | ₹0 | ₹0 | ₹0 | ₹60.08 Lakh | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Debt (computed) | ₹3.93 Cr | ₹3.15 Cr | ₹3.21 Cr | ₹3.08 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| Current Liabilities | ₹33.8 Cr | ₹9.26 Cr | ₹2.7 Cr | ₹2.06 Cr | ₹6.28 Cr | ₹7.16 Cr | ₹5.72 Cr | ₹8.81 Lakh |
| Total Liabilities | ₹38.56 Cr | ₹12.54 Cr | ₹5.91 Cr | ₹4.54 Cr | ₹6.28 Cr | ₹7.16 Cr | ₹5.72 Cr | ₹8.81 Lakh |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹1.93 Cr | ₹3.45 Cr | -₹3 Cr | -₹3.23 Cr | -₹2.34 Cr |
| Investing Cash Flow | -₹1.64 Cr | -₹16.45 Cr | -₹28.29 Cr | ₹53.78 Lakh | ₹41.83 Lakh |
| Financing Cash Flow | -₹1.71 Lakh | -₹43.65 Lakh | ₹47.88 Cr | ₹3.08 Cr | ₹0 |
| Capital Expenditure | ₹4.25 Lakh | ₹72,000 | ₹1.84 Lakh | ₹0 | ₹8.05 Lakh |
| Free Cash Flow (computed) | ₹1.89 Cr | ₹3.45 Cr | -₹3.02 Cr | -₹3.23 Cr | -₹2.42 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | ₹26.88 Lakh | -₹13.44 Cr | ₹16.59 Cr | ₹39.34 Lakh | -₹1.93 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹51.66 Cr | ₹36.01 Cr | ₹31.56 Cr | ₹12.11 Cr | ₹13.56 Cr | ₹8.34 Cr | ₹5.77 Cr | ₹5.3 Cr |
| Other Income | ₹1.62 Cr | ₹1.43 Cr | ₹1 Cr | ₹82.24 Lakh | ₹1.06 Cr | ₹93.14 Lakh | ₹85.82 Lakh | ₹57.79 Lakh |
| Total Income | ₹53.28 Cr | ₹37.44 Cr | ₹32.56 Cr | ₹12.94 Cr | ₹14.62 Cr | ₹9.27 Cr | ₹6.63 Cr | ₹5.88 Cr |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹46.55 Cr | ₹33.85 Cr | ₹39.78 Cr | ₹10.75 Cr | ₹9.76 Cr | ₹7.88 Cr | ₹5.36 Cr | ₹5.47 Cr |
| Changes in Inventories | ₹2.49 Cr | ₹2.13 Cr | -₹9.26 Cr | -₹69.84 Lakh | ₹3.96 Cr | -₹1.5 Cr | -₹59.33 Lakh | -₹1.19 Cr |
| Employee Benefit Expense | ₹24.62 Lakh | ₹22.46 Lakh | ₹18.82 Lakh | ₹21.19 Lakh | ₹17.66 Lakh | ₹17.83 Lakh | ₹14.02 Lakh | ₹17.29 Lakh |
| Finance Costs | ₹24.75 Lakh | ₹19.09 Lakh | ₹7.86 Lakh | ₹7.67 Lakh | ₹5.98 Lakh | ₹10.61 Lakh | ₹4.06 Lakh | ₹7.11 Lakh |
| Depreciation & Amortisation | ₹9.42 Lakh | ₹7.38 Lakh | ₹4.49 Lakh | ₹4.31 Lakh | ₹3.98 Lakh | ₹4.58 Lakh | ₹4.26 Lakh | ₹49,200 |
| Other Expenses | ₹79.07 Lakh | ₹47.97 Lakh | ₹35.46 Lakh | ₹84.52 Lakh | ₹66.23 Lakh | ₹82.27 Lakh | ₹60.39 Lakh | ₹61.76 Lakh |
| Total Expenses | ₹50.42 Cr | ₹36.95 Cr | ₹31.18 Cr | ₹11.23 Cr | ₹14.65 Cr | ₹7.53 Cr | ₹5.6 Cr | ₹5.15 Cr |
| Profit Before Exceptional Items & Tax | ₹2.86 Cr | ₹48.75 Lakh | ₹1.38 Cr | ₹1.71 Cr | -₹3.54 Lakh | ₹1.74 Cr | ₹1.03 Cr | ₹73.2 Lakh |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹2.86 Cr | ₹48.75 Lakh | ₹1.38 Cr | ₹1.71 Cr | -₹3.54 Lakh | ₹1.74 Cr | ₹1.03 Cr | ₹73.2 Lakh |
| Total Tax Expense | ₹54.46 Lakh | -₹26.86 Lakh | ₹56.47 Lakh | ₹14.66 Lakh | ₹19.14 Lakh | ₹60.94 Lakh | ₹3.36 Lakh | ₹14.33 Lakh |
| Net Profit | ₹2.32 Cr | ₹75.61 Lakh | ₹81.59 Lakh | ₹1.56 Cr | -₹22.68 Lakh | ₹1.13 Cr | ₹99.77 Lakh | ₹58.87 Lakh |
| Other Comprehensive Income | -₹40.26 Lakh | -₹6.22 Lakh | -₹18.07 Lakh | ₹14.26 Lakh | -₹46.7 Lakh | -₹9.19 Lakh | -₹15.18 Lakh | ₹22.42 Lakh |
| Total Comprehensive Income | ₹1.92 Cr | ₹69.39 Lakh | ₹63.52 Lakh | ₹1.7 Cr | -₹69.38 Lakh | ₹1.04 Cr | ₹84.59 Lakh | ₹81.29 Lakh |
| EBITDA (computed) | ₹3.2 Cr | ₹75.22 Lakh | ₹1.5 Cr | ₹1.83 Cr | ₹6.42 Lakh | ₹1.89 Cr | ₹1.11 Cr | ₹80.81 Lakh |
| Basic EPS | ₹0.04 | ₹0.01 | ₹0.01 | ₹0.03 | ₹-0.01 | ₹0.02 | ₹0.02 | ₹0.01 |
| Diluted EPS | ₹0.04 | ₹0.01 | ₹0.01 | ₹0.03 | ₹-0.01 | ₹0.02 | ₹0.02 | ₹0.01 |
| Segment · Q1 FY26 (latest quarter) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Pharmaceuticals | ₹12.11 Cr | ₹1.78 Cr | ₹20.73 Cr | ₹9.69 Cr |
| Trading in Securities | ₹0 | ₹0 | ₹89.32 Lakh | ₹0 |
| Segment · FY 2025 (annual) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Pharmaceuticals | ₹32.96 Cr | ₹3.73 Cr | - | - |
| Trading in Securities | ₹30,000 | -₹15,000 | - | - |
Shareholding Pattern of Genpharmasec Limited
As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 29.98%, retail and other public shareholders hold 70.02% of Genpharmasec Limited. The company had 102,252 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 29.98% | 29.98% | 29.98% | 29.98% | 29.98% | 29.98% |
| Public | 70.02% | 70.02% | 70.02% | 70.02% | 70.02% | 70.02% |
| Mar 2026 | Mar 2025 | Mar 2024 | |
|---|---|---|---|
| Promoters | 29.98% | 29.98% | 29.98% |
| Public | 70.02% | 70.02% | 70.02% |
| Promoter change (YoY, %pts) | +0.00 | +0.00 | - |
Charges & Borrowings of Genpharmasec Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Dec 2025 | Hdfc Bank Limited | ₹10 Cr | Open |
| 06 May 2025 | Others | ₹2.5 Cr | Open |
| 03 Jul 2025 | Hdfc Bank Limited | ₹1.5 Cr | Satisfied |
| 23 May 2025 | Hdfc Bank Limited | ₹2.5 Cr | Satisfied |
| 24 May 2023 | Others | ₹3 Cr | Satisfied |
Total charge records: 9 View all charges
Employees and EPFO Compliance at Genpharmasec Limited
View historical data on people associated with Genpharmasec Limited, including employment history and EPFO contributions.
Employee and EPFO history for Genpharmasec Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Genpharmasec Limited
GST registrations and filing compliance for Genpharmasec Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Genpharmasec Limited
Credit ratings, litigation, and regulatory alerts for Genpharmasec Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Genpharmasec Limited
MSME payment history for Genpharmasec Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Genpharmasec Limited
Corporate group structure for Genpharmasec Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Genpharmasec Limited
MCA filings and documents for Genpharmasec Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Genpharmasec Limited
Frequently Asked Questions about Genpharmasec Limited
Genpharmasec Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 16 November 1992 (34+ years old) and is registered under CIN L24231MH1992PLC323914. Listed on BSE: 531592.
Genpharmasec Limited reported revenue of ₹139.94 Cr for FY 2026 (up 314.98% YoY) based on consolidated BSE filings.
The current directors of Genpharmasec Limited are:
- Rajesh Mirchumal Sadhwani - Director
- Sneha Sadhwani - Director
- Sachin Prakash Aphandkar - Director
- Sohan Chaturvedi - Whole-Time Director
- Siddhesh Shankar Shende - Director
- Mayur Bhatt - Director
The primary industry of Genpharmasec Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Genpharmasec Limited is listed on BSE with code 531592.
Genpharmasec Limited can be reached at the registered office: Office No. 104 & 105 1St Floor Gundecha Industrial Premises Co – Op Soc. Ltd.Akurli Road Kand, Ivali East, Mumbai, Maharashtra, India – 400101, or through the website genpharmasec.com.